Updated efficacy of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC).
暂无分享，去创建一个
C. Atreya | J. Schellens | J. Tabernero | J. Bendell | M. Motwani | P. O'dwyer | K. Muro | J. Greger | M. Gordon | F. Rangwala | T. André | E. Cutsem | R. Sidhu | K. Orford | R. Corcoran | Yuehui Wu | A. McRee | R. V. Geel